MBX insider transaction filings
MBX Biosciences, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-05. Screen MBX transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 3 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 1 leg across 1 filing by 1 insider — 370 shares, $24,335 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 4.
- Largest priced transaction: sale of 370 shares @ $65.77 ($24,335) by Azoulay Salomon, filed 2026-08-05.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Azoulay Salomon — Chief Medical Officer | 1 | — | 1 leg · 370 sh · $24,335 | — |
| Hoerter Steven L. — President and CEO, Director | 1 | — | — | 2 |
| Smither John W — Chief Financial Officer | 1 | — | — | 2 |
Recent Form 4 filings — MBX Biosciences, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-05 | 4 | Azoulay Salomon — Chief Medical Officer | Sale (S): 370 @ $65.77 | EDGAR |
| 2026-08-04 | 4 | Hoerter Steven L. — President and CEO, Director | Grant/award (A): 71,000 @ $0 · Grant/award (A): 331,000 (derivative) @ $0 | EDGAR |
| 2026-08-04 | 4 | Smither John W — Chief Financial Officer | Grant/award (A): 28,000 @ $0 · Grant/award (A): 130,000 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Ryder Steven — Director | Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Aynechi Tiba — Director | Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Stelzer Laurie — Director | Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Hoerter Steven L. — Director | Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Pescovitz Ora H. — Director | Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Heron Patrick J — Director, 10% owner | Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Mathers Edward T — Director | Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2026-05-11 | 4 | Azoulay Salomon — Chief Medical Officer | Option exercise (M): 55,000 @ $10.46 · Sale (S): 55,000 @ $38.38 · Option exercise (M): 15,003 @ $16 · Sale (S): 15,003 @ $38.30 · Option exercise (M): 55,000 (derivative) @ $0 · Option exercise (M): 15,003 (derivative) @ $0 | EDGAR |
| 2026-05-08 | 4 | Azoulay Salomon — Chief Medical Officer | Sale (S): 231 @ $29.54 | EDGAR |
| 2026-05-08 | 4 | Hawryluk P. Kent — President & CEO, Director | Sale (S): 607 @ $29.54 | EDGAR |
| 2026-05-04 | 4 | Hoerter Steven L. — Director | Grant/award (A): 11,938 @ $0 · Grant/award (A): 74,249 (derivative) @ $0 | EDGAR |
| 2026-04-22 | 4/A | Hoerter Steven L. — Director | Grant/award (A): 0 (derivative) @ $0 | EDGAR |
| 2026-04-22 | 4/A | Hoerter Steven L. — Director | Grant/award (A): 33,751 (derivative) @ $0 | EDGAR |
| 2026-03-16 | 4 | Hawryluk P. Kent — President & CEO, Director | Purchase (P): 18,500 @ $28.41 | EDGAR |
| 2026-02-27 | 4 | Hawryluk P. Kent — President & CEO, Director | Option exercise (M): 28,768 @ $16 · Option exercise (M): 28,768 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Azoulay Salomon — Chief Medical Officer | Grant/award (A): 15,000 @ $0 · Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Bartram Richard — Chief Financial Officer | Grant/award (A): 15,000 @ $0 · Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Hawryluk P. Kent — President & CEO, Director | Grant/award (A): 35,250 @ $0 · Grant/award (A): 164,500 (derivative) @ $0 | EDGAR |
| 2026-01-22 | 4 | Stelzer Laurie — Director | Grant/award (A): 32,000 (derivative) @ $0 | EDGAR |
| 2025-11-25 | 4 | Hoerter Steven L. — Director | Grant/award (A): 8,000 (derivative) @ $0 | EDGAR |
| 2025-11-07 | 4 | Hoerter Steven L. — Director | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2025-10-28 | 4 | Hawryluk P. Kent — President & CEO, Director | Option exercise (M): 182,859 @ $3.25 · Option exercise (M): 182,859 (derivative) @ $0 | EDGAR |
| 2025-10-21 | 4 | Hawryluk P. Kent — President & CEO, Director | Purchase (P): 20,000 @ $13.64 | EDGAR |
| 2025-10-20 | 4 | Hoerter Steven L. — Director | Purchase (P): 20,000 @ $13.25 | EDGAR |
| 2025-09-30 | 4 | Heron Patrick J — Director, 10% owner FHMLS X, L.P. — 10% owner FHMLS X, L.L.C. — 10% owner Topper James N — 10% owner Frazier Life Sciences X, L.P. — 10% owner | Purchase (P): 666,666 @ $18 | EDGAR |
| 2025-06-06 | 4 | Ryder Steven — Director | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Aynechi Tiba — Director | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Hoerter Steven L. — Director | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Pescovitz Ora H. — Director | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Heron Patrick J — Director, 10% owner | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Mathers Edward T — Director, 10% owner | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | CORNELIUS JAMES M — Director | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2025-04-10 | 4 | Pescovitz Ora H. — Director | Purchase (P): 7,693 @ $5.89 | EDGAR |
| 2025-04-09 | 4 | Hoerter Steven L. — Director | Grant/award (A): 32,000 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | GORDON CARL L — Director, 10% owner | Purchase (P): 17,962 @ $9.90 · Purchase (P): 29,540 @ $9.85 · Purchase (P): 49,070 @ $10.84 · Purchase (P): 94,100 @ $10.84 | EDGAR |
| 2025-02-19 | 4 | ORBIMED ADVISORS LLC — Director, 10% owner OrbiMed Capital GP VII LLC — Director, 10% owner OrbiMed Genesis GP LLC — Director, 10% owner | Purchase (P): 17,962 @ $9.90 · Purchase (P): 29,540 @ $9.85 · Purchase (P): 49,070 @ $10.84 · Purchase (P): 94,100 @ $10.84 | EDGAR |
| 2025-02-05 | 4 | Azoulay Salomon — Chief Medical Officer | Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2025-02-05 | 4 | Bartram Richard — Chief Financial Officer | Grant/award (A): 95,000 (derivative) @ $0 | EDGAR |
| 2025-02-05 | 4 | Hawryluk P. Kent — President & CEO, Director | Purchase (P): 50,000 @ $10.69 · Grant/award (A): 243,000 (derivative) @ $0 | EDGAR |
| 2024-09-17 | 4 | Heron Patrick J — Director, 10% owner | Conversion (C): 3,927,774 · Purchase (P): 625,000 @ $16 · Conversion (C): 18,922,852 (derivative) · Conversion (C): 28,297,265 (derivative) | EDGAR |
| 2024-09-17 | 4 | Mathers Edward T — Director, 10% owner | Conversion (C): 1,023,103 · Conversion (C): 2,091,383 · Purchase (P): 500,000 @ $16 · Conversion (C): 12,299,854 (derivative) · Conversion (C): 25,142,840 (derivative) | EDGAR |
| 2024-09-17 | 4 | Frazier Life Sciences X, L.P. — 10% owner FHMLS X, L.P. — 10% owner FHMLS X, L.L.C. — 10% owner Topper James N — 10% owner | Conversion (C): 3,927,774 · Purchase (P): 625,000 @ $16 · Conversion (C): 18,922,852 (derivative) · Conversion (C): 28,297,265 (derivative) | EDGAR |
| 2024-09-17 | 4 | BASKETT FOREST — 10% owner | Conversion (C): 1,023,103 · Conversion (C): 2,091,383 · Purchase (P): 500,000 @ $16 · Conversion (C): 12,299,854 (derivative) · Conversion (C): 25,142,840 (derivative) | EDGAR |
| 2024-09-17 | 4 | SANDELL SCOTT D — 10% owner | Conversion (C): 1,023,103 · Conversion (C): 2,091,383 · Purchase (P): 500,000 @ $16 · Conversion (C): 12,299,854 (derivative) · Conversion (C): 25,142,840 (derivative) | EDGAR |
| 2024-09-17 | 4 | GORDON CARL L — Director, 10% owner | Conversion (C): 2,658,428 · Conversion (C): 403,787 · Purchase (P): 500,000 @ $16 · Purchase (P): 250,000 @ $16 · Conversion (C): 12,372,634 (derivative) · Conversion (C): 19,587,284 (derivative) · +1 more | EDGAR |
| 2024-09-17 | 4 | CORNELIUS JAMES M — Director | Conversion (C): 102,082 · Conversion (C): 994,069 (derivative) · Conversion (C): 233,192 (derivative) | EDGAR |
| 2024-09-17 | 4 | ORBIMED ADVISORS LLC — Director, 10% owner OrbiMed Capital GP VII LLC — Director, 10% owner OrbiMed Genesis GP LLC — Director, 10% owner | Conversion (C): 2,658,428 · Conversion (C): 403,787 · Purchase (P): 500,000 @ $16 · Purchase (P): 250,000 @ $16 · Conversion (C): 12,372,634 (derivative) · Conversion (C): 19,587,284 (derivative) · +1 more | EDGAR |
Recent 8-K events — MBX Biosciences, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-27 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-13 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-06-12 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-05 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-11 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-09 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-27 | 8-K | 1.01 — Entry into a Material Definitive Agreement 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=MBX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →